This review aims to collect and introduce the mechanism of CRP and its components in inhibiting cancer, focusing on breast cancer, lung cancer, prostate cancer, hepatic carcinoma, gastric cancer, colorectal cancer, esophageal cancer, cervical cancer, bladder cancer and other cancers with a high diagnosis rate. Here, CRP is linked to hepatocellular carcinoma.